Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q1 FY24 Earnings Presentation
14 slides from Gland Pharma's earnings presentation, Aug 7, 2023
Slide 1: Gland Pharma Limited Financial Results Q1 FY24
Gland Pharma Limited Financial Results Q1’FY24 07th August 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation
Slide 3: Group Financial Highlights (1/4)
Group Financial Highlights (1/4) Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (INR Mn) (INR Mn / %) 57% 80% 7,558 7,558 12,087 12,087 63% 63% 4,828 8,569 7,850 4,202 56% 54% Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 EBITDA (3) / EBITDA Margin (4) PAT / PAT
Slide 4: Gland Financial Highlights (Ex-Cenexi) (2/4)
Gland Financial Highlights (Ex-Cenexi) (2/4) Revenue from Operations EBITDA (1) / EBITDA Margin (2) (INR Mn / %) (INR Mn) -2% 2,699 2,636 2,636 4% 8,569 8,873 8,873 7,850 31% 1,684 30% 30% 21% Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 PBT / PAT / PAT Margin (3) R&D Expenses / (
Slide 5: Group Financial Highlights (3/4)
Group Financial Highlights (3/4) Net Worth (1) Cash and Bank Balances / Net Cash (2) (INR Mn) (INR Mn) 79,587 81,282 37,707 37,669 20,418 16,356 Mar'23 Jun'23 Mar'23 Jun'23 Networth Total Cash Net Cash Net Working Capital (3) Capital Expenditure (INR Mn) (INR Mn) 24,010 687 22,073 414 Mar'23 Jun'23
Slide 6: Group Financial Highlights (4/4)
Group Financial Highlights (4/4) Asset Turnover Ratio (1)(2) ROCE (ex-cash)(3) / ROCE (4) / RONW (5) (%) 2.2 2.2 1.9 21% 17% 12% 13% 11% 10% 0.5 0.5 0.5 13% 11% 10% Total asset turnover Fixed asset turnover Q1 FY23 FY23 Q1 FY24 Q1 FY23 FY23 Q1 FY24 RoCE (Ex-Cash) RoCE RoNW Cash Flow from Operations
Slide 7: P&L Highlights
P&L Highlights Group P&L (INR Mn) Particulars Q1 FY24 Q1 FY23 YoY Q4 FY23 QoQ FY23 Revenue from operations 12,087 8,569 41% 7,850 54% 36,246 Other Income 375 744 -50% 389 -4% 2,405 Total Income 12,462 9,313 34% 8,239 51% 38,651 Gross Margin(1) 7,558 4,828 57% 4,202 80% 19,392 % margin 63% 56% 54% 54
Slide 8: Q1 FY24 key highlights
Q1 FY24 key highlights ❖ US FDA completed inspections at three of our sterile facilities. ❖ Completed Cenexi’s acquisition and initiated post-merger integration. ❖ Dexrazoxane, the first China product, launched during the quarter. ❖ Revenue increase during Q1FY24 is due to the acquisition of Cenexi
Slide 9: US Market
US Market ▪ Revenue: Group Revenue Contribution Launched 23 molecules in the US market, including Q1 FY24: Rs. 6,021 Mn | YoY Change: -6% Regadenoson, Ganirelix, Neostigmine & Glycopyrrolate Injection. Increase in volume for some of the key products, such Q1 Q1 as Esmolol, Caspofungin, Rocuronium, H
Slide 10: Europe, Other Core Markets (Canada, Australia and New Zealand)
Europe, Other Core Markets (Canada, Australia and New Zealand) Europe Other Core Markets (Canada, Australia and New Zealand) Group Revenue Contribution Group Revenue Contribution Q1 FY24: Rs. 2,224 Mn | YoY Change: 432% Q1 FY24: Rs. 260 Mn | YoY Change: 3% 5% 18% 2% 3% Q1 Q1 Q1 Q1 FY23 FY24 FY23 FY2
Slide 11: Rest of the World Markets
Rest of the World Markets Group Revenue Contribution Rest of the World Markets (Ex-Cenexi) ▪ Our Rest of the World markets accounted for 18% of Q1 FY24: Rs. 2,935 Mn | YoY Change: 193% our Q1FY24 revenue, compared to 12% during Q1 12% FY23. We have seen 62% Y-o-Y growth in revenues for 24% the quart
Slide 12: India (Domestic Market)
India (Domestic Market) Group Revenue Contribution Q1 FY24: Rs. 647 Mn | YoY Change: 29% ▪ The India market accounts for 7% of our Q1FY24 6% 5% revenue and has seen growth of 29% as compared to the same quarter last year. Q1 Q1 FY23 FY24 Gland Revenue Contribution (Ex-Cenexi) Q1 FY24: Rs. 647 Mn | Y
Slide 13: Long term growth drivers
Long term growth drivers 1 ▪ China remains a key geographic focus with received and launched one product during the quarter. Geographic ▪ Enhanced geographical foot-print in Europe through acquisition of Cenexi. Expansion ▪ We are expanding our penetration in the rest of the world markets. 2 Portfol
Slide 14: GLAND
Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District Hyder